Skip to main content

FDNA, PerkinElmer Form Genetic Testing Technology Alliance

NEW YORK – FDNA announced today that it signed a deal to offer its genetic testing technologies and services through PerkinElmer's diagnostic laboratory network.

Boston-based FDNA has developed software called Face2Gene that uses facial anomalies, phenotypic traits, and variant information to diagnose genetic disorders. The software — which uses a proprietary algorithm recently described in Nature Medicine — underlies FDNA's flagship suite of phenotyping applications called Face2Gene Clinic, which is designed to help physicians evaluate patients.

Under the terms of the alliance, PerkinElmer will integrate FDNA's genetic testing technology into its lab ordering and variant analysis workflows as a package called Face2Gene Labs. Additional terms of the deal were not disclosed.

"Without the phenotype, a crucial element of the diagnostic workflow is missing," FDNA CMO Karen Gripp said in a statement. "With this integration, we’re revolutionizing the standard of care where eventually all genetic testing will be influenced and improved by [next-generation phenotyping] technologies."

PerkinElmer CSO Madhuri Hegde added in the statement that the deal will help supplement the Waltham, Massachusetts-based company's existing genomic testing portfolio. In late 2018, PerkinElmer selected BioDiscovery's NxClinical software for genomic data analysis for its services.